MYIA
ALNY icon

Mount Yale Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mount Yale Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$418K Buy
+1,263
New +$430K 0.01% 775
2025
Q3 		– Sell
-113
Closed -$36.8K – 708
2025
Q2 		$36.8K Buy
+113
New +$31.3K ﹤0.01% 897

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mount Yale Investment Advisors's ALNY Position: Q1 2026 in Review

Mount Yale Investment Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 1,263 shares worth $418K. The stake represents 0.01% of the portfolio and ranks #775 among its holdings. This is a return to the name: Mount Yale Investment Advisors previously reported a position in ALNY as recently as Q2 2025.

Mount Yale Investment Advisors first reported a position in ALNY in Q2 2025 and has held it in 2 quarters since. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Mount Yale Investment Advisors held 1,263 shares of Alnylam Pharmaceuticals worth $418K as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Mount Yale Investment Advisors position in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.01% of Mount Yale Investment Advisors's portfolio in Q1 2026, its #775 holding.
  • Mount Yale Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.